Mrs. Alwiene was diagnosed with stage 2 breast cancer in 2012. Initially, she only wanted to use ECCT, hoping the cancer would disappear without surgery or chemotherapy. However, because there was no excretion of dead cells through bodily processes such as urination or defecation, the accumulation of dead cells in the initial tumor area caused inflammation. This led her to decide on a mastectomy to remove her left breast. Pathology results showed invasive ductal carcinoma grade 3 with IHC results indicating triple-negative status—a type of breast cancer with the highest aggressiveness and unsuitable for anti-ER, anti-PR, or anti-HER2 therapies. Mrs. Alwiene refused conventional chemotherapy and decided to continue using the ECCT device to prevent recurrence and metastasis. At the age of 75 in 2022, Mrs. Alwiene celebrated 10 years as a cancer survivor, remaining disease-free, healthy, and active.
Far right: Mammography, ultrasound, and ECVT results from 2012 showing a mass in the left breast. Second from the right: Pathology and IHC results after the 2015 mastectomy indicating invasive ductal carcinoma mamae grade 3 with triple-negative IHC, alongside a clean ECVT result. Second from the left: Abdominal and thoracic organ examinations (not displayed) from 2022 showing no signs of metastasis. Far left: A photo of Mrs. Alwiene at age 72 in 2024, appearing healthy and active.
Mrs. Alwiene was diagnosed with stage 2 breast cancer in 2012. Initially, she relied on ECCT, hoping the tumor would vanish without surgery or chemotherapy. However, due to the lack of excretion of dead cells through bodily processes such as urination or defecation, dead cells accumulated around the tumor mass, causing inflammation. The tumor mass tended to grow but seemed to detach from its roots, appearing to float under the skin. Concerned about the potential for ulceration, Mrs. Alwiene decided to undergo a mastectomy to remove her left breast.
Grade 3 cancers (a high malignancy level for breast cancer) can experience rapid cell death when exposed to electrical fields. Cancer cells’ responsiveness to ECCT increases with malignancy level due to their higher electrical polarity, making them more susceptible to external electrical fields, particularly during cell division. However, the position and type of dead cells play a crucial role in determining whether excretion occurs effectively. High-grade cancers generally contain low lipid compounds, making dead cells less sticky and easier to excrete through blood vessels and bodily processes like urination, sweating, and defecation. However, cancers with high calcification levels may experience excretion blockages due to dense calcium components obstructing blood vessels. High-grade but low-calcification types are the easiest to treat with ECCT.
In Mrs. Alwiene’s case, the tumor appeared to be a high-grade and high-calcification type. ECCT exposure led to relatively rapid cell death, but excretion was limited. The tumor’s surface position also hindered excretion due to minimal blood vessels in the area. After using ECCT for a year, Mrs. Alwiene decided to proceed with surgery. Generally, 3-4 months of ECCT usage is sufficient to weaken tumor cells and detach the tumor mass from surrounding tissues like muscles, blood vessels, and other structures, facilitating surgery. After 3-4 months of ECCT, lumpectomy (removal of the lump) is usually sufficient, eliminating the need for radical mastectomy. However, Mrs. Alwiene’s doctor, dealing with one of the early ECCT cases, recommended radical mastectomy.
Pathology results confirmed invasive ductal carcinoma grade 3 with triple-negative IHC results, ruling out anti-ER, anti-PR, or anti-HER2 therapies. Mrs. Alwiene opted not to undergo conventional chemotherapy and continued using the ECCT device to prevent recurrence and metastasis. Triple-negative grade 3 is among the most aggressive types of breast cancer. Mrs. Alwiene continued therapy solely with ECCT. Post-surgery examinations of the breast and other organs, conducted every 6 to 12 months, showed no recurrence or metastasis.
At the age of 75 in 2022, Mrs. Alwiene celebrated 10 years as a cancer survivor, remaining disease-free, healthy, and active.
Wishing continued health for Mrs. Alwiene.
